Dawn K Smith1, Michelle Van Handel2, Jeremy Grey3. 1. Division of HIV/AIDS Prevention (DHAP), National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention (CDC), Atlanta, GA. Electronic address: dsmith1@cdc.gov. 2. NCHHSTP, CDC, Atlanta, GA. 3. Division of STD Prevention (DSTDP), NCHHSTP, CDC, Atlanta, GA.
Abstract
PURPOSE: Effectively measuring progress in delivering HIV pre-exposure prophylaxis (PrEP) requires subnational estimates of the number of adults with indications for its use that account for differences in HIV infection rates by transmission risk (risk) group and race/ethnicity. METHODS: We applied a multiplier method with 2015 Centers for Disease Control and Prevention surveillance data on proportions of HIV diagnoses by race/ethnicity and risk group and population-based estimates of risk group sizes to derive estimated numbers of adults with indications by risk group (men who have sex with men [MSM], heterosexually active adults [HET], and persons who inject drugs [PWID]) by race/ethnicity in each jurisdiction. RESULTS: An estimated 1.1 million adults had indications for PrEP use in 2015: 813,970 MSM, 258,080 HET, and 72,510 persons who inject drugs, and 500,340 blacks, 282,260 Latinos, and 303,230 whites. Among HET, 176,670 females and 81,410 males had indications. The proportions of adults with indications in each risk and race/ethnicity group varied by jurisdiction. CONCLUSIONS: Blacks comprised the highest number of adults with indications showing that increasing PrEP use in this population must be the highest priority. MSM remain a priority because of the high number with indications. These estimates can be used as denominators to assess PrEP coverage and impact on HIV incidence at subnational levels. Published by Elsevier Inc.
PURPOSE: Effectively measuring progress in delivering HIV pre-exposure prophylaxis (PrEP) requires subnational estimates of the number of adults with indications for its use that account for differences in HIV infection rates by transmission risk (risk) group and race/ethnicity. METHODS: We applied a multiplier method with 2015 Centers for Disease Control and Prevention surveillance data on proportions of HIV diagnoses by race/ethnicity and risk group and population-based estimates of risk group sizes to derive estimated numbers of adults with indications by risk group (men who have sex with men [MSM], heterosexually active adults [HET], and persons who inject drugs [PWID]) by race/ethnicity in each jurisdiction. RESULTS: An estimated 1.1 million adults had indications for PrEP use in 2015: 813,970 MSM, 258,080 HET, and 72,510 persons who inject drugs, and 500,340 blacks, 282,260 Latinos, and 303,230 whites. Among HET, 176,670 females and 81,410 males had indications. The proportions of adults with indications in each risk and race/ethnicity group varied by jurisdiction. CONCLUSIONS: Blacks comprised the highest number of adults with indications showing that increasing PrEP use in this population must be the highest priority. MSM remain a priority because of the high number with indications. These estimates can be used as denominators to assess PrEP coverage and impact on HIV incidence at subnational levels. Published by Elsevier Inc.
Authors: Meredith E Clement; Barbara E Johnston; Cedar Eagle; Destry Taylor; Anna Lina Rosengren; Benjamin A Goldstein; Arlene C Seña Journal: AIDS Patient Care STDS Date: 2019-06-24 Impact factor: 5.078
Authors: Julia L Marcus; Kenneth Levine; Chris Grasso; Douglas S Krakower; Victoria Powell; Kenneth H Mayer Journal: Am J Public Health Date: 2018-12 Impact factor: 9.308
Authors: Sarah J Willis; Noelle M Cocoros; Liisa M Randall; Aileen M Ochoa; Gillian Haney; Katherine K Hsu; Alfred DeMaria; Michael Klompas Journal: Curr Infect Dis Rep Date: 2019-08-26 Impact factor: 3.725
Authors: Hyun Jin Song; Patrick Squires; Debbie Wilson; Wei-Hsuan Lo-Ciganic; Robert L Cook; Haesuk Park Journal: JAMA Date: 2020-07-28 Impact factor: 56.272
Authors: Julie E Myers; Zoe R Edelstein; Demetre C Daskalakis; Anisha D Gandhi; Kavita Misra; Alexis V Rivera; Paul M Salcuni; Kathleen Scanlin; Chi-Chi Udeagu; Sarah L Braunstein Journal: Am J Public Health Date: 2018-11 Impact factor: 9.308
Authors: Avy A Skolnik; Barbara G Bokhour; Allen L Gifford; Brigid M Wilson; Puja Van Epps Journal: J Gen Intern Med Date: 2019-11-08 Impact factor: 5.128
Authors: Dawn K Smith; Patrick S Sullivan; Betsy Cadwell; Lance A Waller; Azfar Siddiqi; Robertino Mera-Giler; Xiaohong Hu; Karen W Hoover; Norma S Harris; Scott McCallister Journal: Clin Infect Dis Date: 2020-12-15 Impact factor: 9.079